X0206 3 2021-10-28 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780662 PISKEL KYLE C/O ADAPTIVE BIOTECHNOLOGIES CORP. 1165 EASTLAKE AVE E SEATTLE WA 98109 0 1 0 0 Principal Accounting Officer Common Stock 2862 D Stock Option (Right to Buy) 6.32 2026-11-08 Common Stock 2500 D Stock Option (Right to Buy) 6.55 2028-10-01 Common Stock 11980 D Stock Option (Right to Buy) 7.80 2029-04-23 Common Stock 3750 D Stock Option (Right to Buy) 27.29 2029-11-14 Common Stock 4900 D Stock Option (Right to Buy) 28.32 2030-02-27 Common Stock 13474 D Stock Option (Right to Buy) 45.82 2030-09-24 Common Stock 15000 D Stock Option (Right to Buy) 43.68 2031-03-04 Common Stock 7154 D The options are fully vested. The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on October 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on September 24, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Mr. Piskel was designated Principal Accounting Officer on October 28, 2021. /s/ Kyle Piskel by Eric Billings, Attorney in Fact 2021-11-03